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Abstract
The neuromuscular disease spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality, resulting from low levels of full-length
survival motor neuron (SMN) protein. Despite having a good understanding of the underlying genetics of SMA, the molecular pathways
downstream of SMN that regulate disease pathogenesis remain unclear. The identification of molecular perturbations downstream of SMN is
required in order to fully understand the fundamental biological role(s) for SMN in cells and tissues of the body, as well as to develop a range of
therapeutic targets for developing novel treatments for SMA. Recent developments in proteomic screening technologies have facilitated proteome-
wide investigations of a range of SMA models and tissues, generating novel insights into disease mechanisms by highlighting conserved changes
in a range of molecular pathways. Comparative analysis of distinct proteomic datasets reveals conserved changes in pathways converging on
GAP43, GAPDH, NCAM, UBA1, LMNA, ANXA2 and COL6A3. Proteomic studies therefore represent a leading tool with which to dissect the
molecular mechanisms of disease pathogenesis in SMA, serving to identify potentially attractive targets for the development of novel therapies.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
disease, primarily characterised by loss of motor neurons
from the anterior horn of spinal cord and atrophy of
skeletal musculature. The disease is considered to represent a
“continuum of clinical severity” [1], but is broadly subdivided
into four sub-types, depending on the developmental milestones
that are reached: type 1 (severe), type 2 (intermediate), type 3
(mild) and type 4 (adult-onset) [1]. Type 1 SMA is the leading
genetic cause of infantile death in the western world and infants
typically die before the age of two due to respiratory failure [2,3].
The cause of SMA for the majority (>95%) of patients is a
loss-of-function defect in the SMN1 gene, resulting in reduced
levels of the ubiquitously-expressed survival of motor neuron
(SMN) protein [4]. Although most humans possess at least one
copy of an additional – and almost identical – SMN2 gene,
protein translated from SMN2 is much less stable and unable to
fully compensate for loss of SMN1 [4–6]. The severity of the
disease is largely dependent upon the number of SMN2 copies
that are present. Thus, patients with the most severe phenotypes
tend to have a lower copy number of SMN2 [7].
At present, there are no disease modifying treatments
available for SMA, and palliative support is the best that can be
offered to patients. However, significant progress has been
made over the last two decades in terms of both basic research
and pre-clinical development, leading to the identification of
several promising therapeutic approaches entering clinical
trials. Almost all of this therapeutic work has focused
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on identifying compounds aimed at targeting either SMN2
promoter activation, modulation of splicing, or SMN1
replacement gene therapy [8]. In contrast, the ability to identify
potential non SMN-focused therapeutic targets has been
hampered by a lack of understanding of the core molecular
pathways acting downstream from SMN to modulate disease
pathogenesis in SMA [9].
SMN is a ubiquitously expressed protein with a role in the
assembly of small nuclear ribonucleic proteins (snRNPs) in the
cytoplasm and subsequent transport into the nucleus for RNA
splicing [4,10]. To do this, SMN functions as a core complex
with at least eight other proteins: gemins 2–8 and unrip. In
addition to this well-characterised housekeeping role, SMN
appears to interact with several other proteins required for the
transport and correct localisation of mRNAs in axons [11–13].
Whilst some of these SMN interactions are relatively stable
(in the case of the core complex with gemin proteins), there
are many other interactions that are expected to be more
transient [14]. A search of two protein interaction databases,
Biomolecular Interaction Network Database (BIND) and the
Molecular INTeraction database (MINT), suggests that in
excess of 100 proteins have the potential to interact with SMN.
Given the potential size of the “SMN interactome” (Fig. 1), and
the fact that each of those interacting proteins may also have
their own unique “interactome”, it seems highly probable that
a reduction of SMN should have significant downstream
molecular consequences affecting a range of different target
proteins and pathways.
Recent advances in proteomic technologies have enabled
researchers to take an unbiased, global view of the proteome,
Fig. 1. The SMN interactome. Ingenuity Pathway Analysis (IPA) software-based identification of all known interacting partners of SMN protein reported in the
published literature. Candidate interactors are organised based on their predominantly reported subcellular localisation and does not mean that they are exclusively
restricted to these positions. These interactions are direct (solid lines) or indirect (dotted lines), and may have been reported following identification at the genomic,
transcriptomic or proteomic (DNA, RNA and/or protein) level. As a result, the schematic presented here represents the known “interactome” for SMN as identified
by IPA.
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and to conduct quantitative comparisons and characterisations
of disease-relevant tissues and model systems relevant to a
broad range of conditions affecting human health. Such
technologies therefore provide un-paralleled opportunities to
accurately monitor and quantify downstream molecular
consequences of SMN depletion in vivo and in vitro. It is
therefore not surprising that proteomic approaches have been
employed by a variety of research groups investigating
mechanisms of disease pathogenesis in SMA.
Despite the wealth of information that proteomic
investigations can generate, two main challenges have
hampered the effective translation of findings from studies
using these approaches to investigate mechanisms of disease
pathogenesis in SMA. The first challenge is that different
proteomic-based studies of SMA have utilised a variety of
model systems and tissue sampling techniques. This has
the potential to result in unavoidable, model/tissue-specific
identified perturbations into proteomic data that are difficult to
isolate from core molecular disease pathways. The second
challenge is that proteomic studies typically yield extensive
lists of proteins exhibiting differential expression profiles based
on an incomplete coverage of the entire proteome, with a select
few candidates from each study often given special attention
for further verification and validation. The selection of such
candidate proteins for further study is often subjective and will
always result in other potentially important proteins and
pathways being overlooked. As a result, there are now a number
of large proteomic datasets from several research groups that
contain crucial, but likely overlooked, information regarding
the core molecular regulators of disease pathogenesis in
SMA. Despite these challenges, the availability of such a broad
range of SMA proteomic datasets presents the opportunity to
generate significant new insights into mechanisms of disease
pathogenesis by interrogating raw datasets to identify common
molecular changes. The identification of conserved alterations
downstream of SMN perturbations, independent of the
experimental model and technical approach used, would
therefore serve to highlight “core” molecular responses to low
levels of SMN. Such “core” responses would likely represent
attractive SMN-independent targets for the development of
novel therapies for SMA.
2. SMA studies employing proteomic screens: an overview
Nine publications to date have used unbiased proteomic
comparisons for the identification of differentially-expressed
proteins in SMA (Table 1). These studies are considered
unbiased because they did not depend on the use of capture or
array technology for enrichment of differentially expressed
proteins. Instead, the entire proteome was subject to analysis
using a variety of protein separation and mass spectrometry
approaches. As expected, there is a clear correlation between
the precise methodology used and the number of differentially
expressed proteins identified in each study; 2D-gel based
studies yielded far fewer proteins than more recently-developed
isobaric (e.g. iTRAQ) or label-free technologies, even when
identical mass spectrometry instrumentation was used. Despite
the relatively small number of studies, both in-vivo and in-vitro
studies are represented, incorporating experimental assessment
of both mouse models and SMA patient samples (Table 1). The
studies include comparisons made of mature cells and tissues
[15–17,19–22], as well as comparisons of cell types at various
stages of cellular differentiation, including undifferentiated and
differentiated embryonic stem cells [23], induced pluripotent
stem cell-derived motor neurons [16], and Schwann cells [18].
Also noteworthy is that three of the studies [15–17] conducted
comparisons using material that was not clinically affected by
SMA (i.e. plasma and skin fibroblasts), thus enabling the
possibility of identifying systemic consequences of reduced
SMN in the absence of overt disease pathology. Taken together,
these nine published proteomic studies cover a broad range of
the most common SMA models, cells and tissues utilised
by the research community. Comparisons between and across
Table 1
Overview of SMA studies employing proteomic screens.
Species Sample type Differentially
expressed
proteins
Analysis platform Protein
database
Reference
Human, SMA I, II
and III
Plasma 84* iTRAQ; MALDI-TOF/TOF (AB Sciex 4800) Unknown [15]
Human, SMA I iPSC-motor neurons 98 iTRAQ; ESI-QTOF (AB Sciex 5600) Swiss-Prot [16]
Skin fibroblasts 18
Human, SMA I Skin fibroblasts 6 2D-gels; ESI-QTOF (unknown) Unknown [17]
Mouse, Taiwanese Schwann cells 195 Label-free; LTQ Orbitrap Velos Pro (Thermo
Scientific)
IPI-mouse [18]
Mouse (normal) NSC34 SMN-knockdown 7 2D-gels; MALDI QTOF (unknown) Unknown [19]
Mouse, severe SMA Hippocampus 39 iTRAQ; ESI-QTOF (Agilent 6520) IPI-mouse [20]
Mouse, severe SMA Hippocampal synaptosomes 52 iTRAQ; ESI-QTOF (Agilent 6520) IPI-mouse [21]
Mouse, severe SMA at
P5 (symptomatic)
Muscle 23 Label-free; LTQ Orbitrap XL (Thermo Scientific) Swiss-Prot [22]
Mouse, severe SMA Undifferentiated embryonic stem cells 4 2D-gels; MALDI-TOF/TOF (AB Sciex 4800) NCBInr [23]
Differentiated embryonic stem cells 11
The nine publications that have used unbiased proteomic comparisons to date for the identification of differentially-expressed proteins in SMA.
* These data resulted from re-analysis of a previously published raw dataset [24].
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experimental datasets from these studies are therefore likely to
identify conserved molecular responses to low levels of SMN
directly relevant to disease pathogenesis.
3. Multi-study proteomic identification of conserved
molecular responses to reduced levels of SMN in SMA
Review of the differentially expressed proteins from the
studies detailed in Table 1 identified 29 proteins that showed
conserved changes across two or more separate proteomic-
based studies of SMA (Table 2). Of these 29 proteins, 19
revealed increased expression in response to low levels of SMN
and 10 revealed decreased expression levels (Table 2). These
proteins therefore represent a novel potential “molecular
fingerprint” of SMA pathogenesis.
Of the 10 proteins that were decreased in expression in SMA
cell and tissue samples, four were found to be consistently
decreased across three separate studies (Table 2), suggesting
that they may represent a conserved response to lowered
levels of SMN and as a result warrant significant further
experimental attention. One of these proteins, ubiquitin
activating enzyme 1 (UBA1), has been strongly linked to
neurodegenerative pathways across a range of diseases,
including SMA [34]. Of particular relevance too is that
mutations in the human UBE1 gene, which encodes UBA1
protein, are associated with a rare X-linked infantile form of
SMA [30,31]. Despite differences in experimental platforms,
species and tissue/cell type utilised in the quantitative
proteomic studies, the percentage reduction of UBA1 is
strikingly comparable across all three studies. Aghamaleky
Sarvestany et al. [18] detected a 50% decrease of UBA1 in
SMA mouse Schwann cells compared to control; Wishart et al.
[21] detected a 57% decrease in SMA mouse hippocampal
synaptosomes; Fuller et al. [16] detected a 52% decrease in
UBA1 in SMA patient iPSC-derived motor neurons.
Further experimental evidence has verified that UBA1 levels
are significantly depleted at both the gene and protein level in
iPS-derived motor neurons from three individual SMA patients
[16], and at the tissue and cellular level in mouse models of
SMA. The reduction in mouse models of SMA contributes,
at least in part, to widespread perturbations in ubiquitin
homeostasis [18,21,35]. Importantly, experimental suppression
of UBA1, using both genetic and pharmacological approaches,
was sufficient to fully phenocopy the SMA motor neuron
phenotype in zebrafish [21], and pharmacological suppression of
UBA1 in normal Schwann cells phenocopied the differentiation/
myelination defects observed in SMASchwann cells [18].Thus,
the robust finding of depleted levels of UBA1 across multiple
proteomic studies of SMA suggests that this protein is likely to
be a major contributor to disease pathogenesis in SMA.
Also reduced across three separate comparisons was the
traditional “housekeeping” glycolytic enzyme, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (Table 2). The reduction
seen in SMA mouse Schwann cells (56% [18]) was slightly
greater than that seen across the isoforms of GAPDH that
were detected in the SMA mouse hippocampus comparison
(approximately 40% reduction on average [20]). It was not
possible to compare the average percentage reduction seen in
SMA patient plasma samples with the other studies because
proteins were expressed according to their correlation with the
Modified Hammersmith Functional Motor Scale, rather than
relative fold change [15].
Evidence linking GAPDH directly to SMN can also be found
from a previous high-throughput yeast two-hybrid screen [33],
although (as with other protein candidates identified from
similar high-throughput studies) it would appear that this
association has since been overlooked. Notably, the observation
of reduced levels of GAPDH in SMA is consistent with a role as
an SMN-interactor, since many other SMN-binding proteins
are also dysregulated and/or differentially expressed in SMA
models [14,21,36,37].Although it has been widely implicated in
cellular metabolic processes, GAPDH has also been linked to a
range of pathways with particular relevance to the nervous
system and neurodegeneration, including apoptosis [38], and
vesicle and axonal transport [39]. Documented variation in the
mRNA and protein levels of GAPDH in other neuropathological
events has been reported [40], and suggests that it may play a key
role in neurodegenerative processes. Further investigations into
the role of GAPDH in SMA pathogenesis therefore appear
warranted.
In addition to implications for SMA pathogenesis, the
significance of reduced GAPDH in SMA models should be
viewed as a cautionary note, in so far that its use (as well as that
of other housekeeping proteins such as actin and tubulin) as an
internal loading control for gene expression and western blot
analysis may be unreliable [41]. As such, it may be necessary to
revisit candidate proteins and genes from studies that have
concluded little or no correlation with SMA in instances when
levels were normalised to GAPDH (or other “housekeeping”
protein) expression.
Two other proteins whose levels were consistently reduced
across three separate proteomic comparisons were growth-
associated protein 43 (GAP43 or neuromodulin) and neural cell
adhesion molecule (NCAM) (Table 2). Interestingly, both
GAP43 and NCAM are known binding partners of the multi-
functional calcium-binding protein calmodulin [42,43] – which
itself features in Table 2 as a down-regulated protein detected in
two separate proteomic comparisons.
GAP43 levels were reduced by approximately 65% in iPS-
derived SMA motor neurons [16], and by 35% and 22% in the
SMAmouse hippocampus [20] and hippocampal synaptosomes
[21] respectively (Table 2). Similarly, reduced levels of GAP43
have been detected in the CSF of human patients affected by a
wide range of neurological disorders [44], including motor
neuron disease, movement disorders (e.g. Parkinson’s disease)
and multiple sclerosis. Considered to play a key role in axonal
pathfinding, GAP43 is required for survival beyond early
postnatal development in the mouse [45]. Reports have
demonstrated increased levels of GAP43 during axonal growth
in the rat [46] and during axonal regeneration following
neurological injury of toad retinal ganglion cells [47] and the
goldfish retina [48]. Very recently, reduced levels of GAP43
mRNA and protein in axons and growth cones of SMA mice
were reported [32]. SMN appears to be responsible for
regulating the localisation and translation of GAP43 mRNA in
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Table 2
The conserved molecular responses to reduced levels of SMN in SMA.
Proteins with increased expression in SMA models
Protein name Number of
repeat hits
SMA model Additional evidence in the pathophysiology
of SMA
Annexin A2 3 Mouse Schwann cells [18]
Type I patient motor neurons [16]
P5 mouse muscle [22]
• Published interactor of SMN [25].
• Depletion of SMN in the NSC-34 mouse
motor neuron cell line resulted in increased
levels of ANXA2 mRNA [26].
Lamin A/C 3 Mouse Schwann cells [18]
Type I patient motor neurons [16]
P5 mouse muscle [22]
• Published interactor of SMN [25].
• Mutations in the LMNA gene can cause
an SMA phenotype [27,28].
Collagen alpha 3 (VI) 3 Type I patient skin fibroblasts [16]
Type I patient motor neurons [16]
Type I, II and III patient plasma [15]
–
Gelsolin 2 Mouse Schwann cells [18]
Type I, II and III patient plasma [15]
–
Calreticulin 2 Type I patient motor neurons [16]
P5 mouse muscle [22]
• Increased expression verified by western
blotting in SMA mouse and patient muscles
[22].
Tropomyosin 3 2 Mouse hippocampus [20]
Mouse embryonic stem cells (differentiated) [23]
–
ATP synthase subunits 2 Mouse hippocampus synaptosomes [21]
Mouse Schwann cells [18]
–
Actin-related protein 2/3 complex 2 Mouse hippocampus synaptosomes [21]
Type I patient motor neurons [16]
–
Collagen alpha 1 (VI) 2 Type I patient skin fibroblasts [16]
Type I, II and III patient plasma [15]
–
Tubulin alpha 2 Mouse hippocampus synaptosomes [21]
Mouse embryonic stem cells (differentiated) [23]
–
Plectin 2 Mouse Schwann cells [18]
P5 mouse muscle [22]
–
SOD1 2 Mouse Schwann cells [18]
Mouse hippocampus [20]
• SMN overexpression improves
neuromuscular function and motor neuron
survival in SOD1 mice [29].
Serpin H1 2 Mouse Schwann cells [18]
Type I patient motor neurons [16]
–
Annexin A5 2 Mouse embryonic stem cells (differentiated) [23]
Mouse Schwann cells [18]
–
Filamin 2 Mouse Schwann cells [18]
Type I patient motor neurons [16]
–
Collagen alpha 1 (I) 2 Mouse Schwann cells [18]
Type I patient motor neurons [16]
–
Collagen alpha 2 (I) 2 Mouse Schwann cells [18]
Type I patient motor neurons [16]
–
Hypoxia up-regulated protein 1 2 Mouse Schwann cells [18]
Type I patient motor neurons [16]
–
Glucose-6-phosphate isomerase 2 Mouse Schwann cells [18]
P5 mouse muscle [22]
–
Proteins with decreased expression in SMA models
Protein name Number of
repeat hits
SMA model Additional evidence in the pathophysiology
of SMA
UBA1 3 Mouse hippocampus synaptosomes [21]
Mouse Schwann cells [18]
Type I patient motor neurons [16]
• Mutations in the UBE1 gene are
associated with a rare X-linked infantile
form of SMA [30,31].
• Experimental suppression of UBA1
phenocopied the SMA motor neuron
phenotype in zebrafish [21], and
phenocopied the Schwann cell defects
observed in SMA [18].
NCAM 3 Mouse hippocampus [20]
Type I, II and III patient plasma [15]
Type I patient motor neurons [16]
• Atrophic fibres in type I and II SMA
muscle biopsies express high levels of
NCAM.
(continued on next page)
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these axons, and restoration of GAP43 mRNA and protein
levels by overexpression of the mRNA binding proteins, HuD
and IMP1, rescued the axonal growth defects in the SMA mice
[32]. These studies illustrate that GAP43 is implicated in axonal
growth/repair pathways and as such represents a promising
neuronal target for SMA therapy.
NCAM is a cell-surface protein that has been associated
with cell–cell adhesion, neurite outgrowth and plasticity, and
memory formation [49]. Maintenance of NCAM homeostasis is
also important for neuronal growth and survival since both
increased and decreased levels of NCAM have been linked to a
wide range of neurological disorders (reviewed by Gnanapavan
and Giovannoni [50]). For example, whilst levels of NCAM
increase following axonal injury [51,52] and atrophic fibres in
type I and II SMAmuscle biopsies appear to express high levels
of NCAM [53], NCAM deficient mice display hippocampal
dysplasia and loss of septal cholinergic neurons [54]. Increased
life-span and improved behavioural performance were seen in a
mouse model of the motor neuron disease amyotrophic lateral
sclerosis (ALS), following transplantation of human umbilical
cord blood cells carrying adeno-viral vectors expressing a
neuro-protective factor and NCAM [55]. It seems highly
pertinent therefore that future studies should aim to determine
whether modulating the severity of SMA is also possible by
manipulation of NCAM levels, which until now have been
overlooked in terms of their role in SMA pathogenesis.
Of the 10 proteins that revealed increased expression in
SMA cell and tissue samples, three were consistently changed
across three separate proteomic comparisons (Table 2).
Collagen VI, alpha 3 chain (COL6A3) was increased in SMA
patient plasma [15] and in SMA patient fibroblasts and
iPS-derived motor neurons [16]. Of particular interest is
that when SMA fibroblasts were quantitatively compared to
control fibroblasts, 18 proteins were differentially expressed but
only one of these, collagen alpha-3 VI, was also differentially
expressed in the same direction when genetically matched
SMA iPS-derived motor neurons were compared to control
motor neurons.
Overexpression of COL6A3 is also seen in various types of
cancer [56–58] and mutations in this gene can cause Ullrich
congenital muscular dystrophy (CMD) and Bethlem myopathy
[59], both of which involve muscle and connective tissue
problems. Although collagen VI is a well-known extracellular
matrix protein, little is known about the particular characteristics
of the COL6A3 isoform, except that it may play a role in
advanced stages of neural crest development [60].The relevance
of an increase in the levels of COL6A3 in SMA may reflect an
attempted protective response, since an increase in collagen VI
appears to confer neuronal protection under cell stress [61].
Published interactors of SMN, annexin A2 (ANXA2) and
the intermediate filament protein laminA/C (LMNA) [25] were
increased in expression in Schwann cells and muscle from
SMA mice and in iPS-derived motor neurons from an SMA
patient (Table 2). Mutations in LMNA cause a range of
disorders, including muscular dystrophies such as Charcot–
Marie–Tooth disease and Emery–Dreifuss muscular dystrophy
[62]. Given that mutations in the LMNA gene can cause an
SMA phenotype [27,28], it is surprising that further studies to
explore the relationship between LMNA and SMA have not
been pursued.
Depletion of SMN in the NSC-34 mouse motor neuron cell
line resulted in a 50% increase in the levels of ANXA2 mRNA
Table 2 (continued)
Proteins with decreased expression in SMA models
Protein name Number of
repeat hits
SMA model Additional evidence in the pathophysiology
of SMA
GAP43 (neuromodulin) 3 Mouse hippocampus [20]
Mouse hippocampus synaptosomes [21]
Type I patient motor neurons [16]
• Reduced levels of GAP43 mRNA and
protein in axons and growth cones of SMA
mice [32].
• Restoration of GAP43 mRNA and protein
levels rescued axonal growth defects in the
SMA mice [32].
GAPDH 3 Mouse Schwann cells [18]
Mouse hippocampus [20]
Type I, II and III patient plasma [15]
• Published interactor of SMN (from yeast
two-hybrid screen) [33].
Heat shock protein 90B 2 Mouse embryonic stem cells (differentiated) [23]
P5 mouse muscle [22]
–
Calmodulin 2 Mouse hippocampus [20]
Type I patient skin fibroblasts [16]
–
Catalase 2 Type I, II and III patient plasma [15]
Type I patient motor neurons [16]
–
Peroxiredoxin 2 2 Mouse Schwann cells [18]
Type I, II and III patient plasma [15]
–
Aldehyde dehydrogenase 2 Mouse embryonic stem cells (differentiated) [23]
Mouse Schwann cells [18]
–
Alcohol dehydrogenase class 3 2 Mouse Schwann cells [18]
Type I patient motor neurons [16]
–
Individual proteins that were differentially expressed across two or more separate comparisons are shown, along with the number of studies they were identified in
(“repeat hits”), the corresponding SMA model and any additional evidence for a role in the pathophysiology of SMA.
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[26], which correlates well with the 57% increase of ANXA2
protein seen in iPS-derived motor neurons from an SMA
patient [16] (Table 2). Overexpression of ANXA2 by transient
transfection induces the disassembly of Cajal bodies and
relocalisation of coilin [63], the “bridge” protein that mediates
recruitment of SMN to the Cajal body [64]. This is particularly
interesting in the current context, and may offer insight into the
likely downstream consequences of increased ANXA2 in SMA
cells, given that depletion of SMN also disrupts Cajal body
formation and localisation of coilin [65,66].
4. Refinement of single quantitative proteomic datasets
In addition to highlighting conserved changes present across
several studies, review of multi-study proteomic comparisons is
likely to be useful for refining single proteomic datasets by
highlighting potential “false positives”. Differentially expressed
Table 3
Proteins with contradictory expression levels in SMA models.
Protein name Increased in SMA Decreased in SMA
Aspartate aminotransferase P5 mouse muscle [22] Type I patient motor neurons [16]
Caldesmon Mouse Schwann cells [18]
Type I patient motor neurons [16]
Type I patient skin fibroblasts [16]
Catenin alpha Mouse Schwann cells [18] Type I patient motor neurons [16]
Catenin beta Mouse hippocampus synaptosomes [21] Type I patient motor neurons [16]
Endoplasmin Type I patient motor neurons [16] Mouse Schwann cells [18]
Fructose bisphosphate aldolase Mouse Schwann cells [18]
Mouse hippocampus synaptosomes [21]
Mouse hippocampus [20]
Galectin Type I patient motor neurons [16] Mouse (NSC34) cells [19]
Glyoxalase 1 Mouse embryonic stem cells (d) [23] Type I, II and III patient plasma [15]
hnRNP K Mouse Schwann cells [18] Mouse (NSC34) cells [19]
Hspa9/GRP75/stress-70 protein Mouse Schwann cells [18]
Mouse hippocampus synaptosomes [21]
P5 mouse muscle [22]
Mouse embryonic stem cells (d) [23]
HSP90a Mouse hippocampus [20]
Type I patient motor neurons [16]
Mouse hippocampus synaptosomes [21]
Hspd1 Mouse Schwann cells [18] Mouse hippocampus [20]
Mouse hippocampus synaptosomes [21]
Inorganic pyrophosphatase Mouse hippocampus synaptosomes [21] Type I patient motor neurons [16]
Macrophage migration inhibitory factor Mouse hippocampus synaptosomes [21] Type I, II and III patient plasma [15]
MARCKS Mouse hippocampus synaptosomes [21] Mouse hippocampus [20]
Myosin 3 Type I patient motor neurons [16] Type I patient skin fibroblasts [16]
Park7 Mouse hippocampus synaptosomes [21] Type I, II and III patient plasma [15]
Periostin Type I patient motor neurons [16] P5 mouse muscle [22]
Phosphoglycerate kinase 1 Mouse hippocampus synaptosomes [21] Mouse Schwann cells [18]
Phosphoglycerate mutase Mouse hippocampus [20] Mouse hippocampus synaptosomes [21]
Mouse Schwann cells [18]
Profilin 1 Mouse Schwann cells [18] Type I, II and III patient plasma [15]
Prolyl 4-hydroxylase alpha 2 and alpha 1 Type I patient motor neurons [16] Mouse Schwann cells [18]
Reticulon Mouse Schwann cells [18] P5 mouse muscle [22]
Ribosome-binding protein 1 Type I patient motor neurons [16] P5 mouse muscle [22]
SOD1 Mouse Schwann cells [18]
Mouse hippocampus [20]
Type I, II and III patient plasma [15]
Sulphated glycoprotein 1 Mouse hippocampus synaptosomes [21] Mouse Schwann cells [18]
Synaptopodin-2 Type I patient motor neurons [16] Type I patient skin fibroblasts [16]
S100 A4 Mouse Schwann cells [18] Type I, II and III patient plasma [15]
T-complex protein 1 Mouse hippocampus synaptosomes [21]
Mouse Schwann cells [18]
P5 mouse muscle [22]
Mouse hippocampus [20]
UCHL1 Mouse embryonic stem cells (d) [23]
Mouse Schwann cells [18]
Type I patient skin fibroblasts [17]
Mouse hippocampus synaptosomes [21]
Type I patient skin fibroblasts [16]
Type I patient motor neurons [16]
VDAC1 Type I patient skin fibroblasts [16] Mouse Schwann cells [18]
Vimentin P5 mouse muscle [22] Type I patient motor neurons [16]
Zyxin Type I patient motor neurons [16] Type I patient skin fibroblasts [16]
14-3-3 gamma Mouse Schwann cells [18]
Mouse hippocampus synaptosomes [21]
Mouse embryonic stem cells (d) [23]
40S S3 Type I patient motor neurons [16] Mouse Schwann cells [18]
2′,3′-cyclic-nucleotide 3′-phosphodiesterase Type I patient skin fibroblasts [16] Type I patient motor neurons [16]
A number of proteins appear to be increased or decreased in expression in a particular SMA cell type or tissue but showed the opposite trend in another.
(d) = differentiated.
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proteins that one might consider as “false positives” could
arise due to unavoidable imprecisions in tissue sampling
techniques, the impact of genetic diversity between the
individual samples, the heterogeneous nature of some cell
cultures, the developmental status of the samples, or the
differences in disease severity and progression. An example of
the impact of the latter comes fromour own previousworkwhere
we quantitatively compared the proteome of primary skin
fibroblasts fromanSMApatientwith an unaffectedSMAcarrier.
Myogenic cells present in the SMA fibroblast cell line but
undetectable in the other resulted in an apparent increase in the
myoblast-specific protein desmin in the SMA cells [67].
Based on a combined review of raw data concerning
differentially expressed proteins from the studies detailed in
Table 1, 37 proteins were identified that appeared to have
altered expression in one particular SMA cell type or tissue but
with opposing detection in another. These contradictions are
summarised in Table 3. If we were to speculate about these
contradictions in the context of SMA, it would be parsimonious
to suggest that some likely reflect a unique response of that
particular system/cell type to reduced SMN, and could be useful
for explaining the known disparity between vulnerabilities of
distinct cell and tissue types in SMA [3]. However, “. . . nature
seems unaware of our intellectual need for convenience and
unity, and very often takes delight in complication and diversity”
[68], and in reality, the complex diversity of changes observed
between proteomic datasets may simply represent the highly
complex biological systems being examined. Such systems are
not ‘static’andwill represent cells, tissues and organs at different
stages of differentiation, development, and disease time-course.
Thus, the ability to compare data across multiple proteomic
datasets generated from a range of tissue samples offers the
possibility of refining the output of a single dataset in order to
minimise the influence of such variables. The wealth of
proteomic data now available in the public domain makes
it possible for future studies of SMA to undertake such
comparative assessments.
5. Conclusions
Proteomic techniques offer a powerful tool for obtaining
disease-relevant mechanistic insights into SMA. By reviewing
multiple proteomic datasets, it is possible to identify conserved
molecular changes downstream of SMN occurring across a
range of model systems. These changes likely represent “core”
regulators of disease pathogenesis and, as such, may represent
novel therapeutic targets. It will now be important to verify
these changes biochemically in a range of cells and tissues
throughout disease progression and to determine whether their
expression levels correlate with clinical severity. Therapeutic
strategies for pharmacological or genetic manipulation of these
molecules – or manipulation of upstream regulators of groups
of molecules – offer the potential to complement strategies
directed solely at SMN.
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